Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carbonic Anhydrase Inhibitors | 8 | 2021 | 24 | 4.050 |
Why?
|
| Drug Design | 14 | 2021 | 147 | 3.620 |
Why?
|
| Anticonvulsants | 9 | 2021 | 370 | 3.260 |
Why?
|
| Sulfonamides | 4 | 2018 | 259 | 2.000 |
Why?
|
| Piperazines | 6 | 2024 | 231 | 1.910 |
Why?
|
| Alzheimer Disease | 4 | 2024 | 766 | 1.600 |
Why?
|
| Molecular Docking Simulation | 7 | 2024 | 113 | 1.450 |
Why?
|
| Amyloid beta-Peptides | 3 | 2024 | 206 | 1.430 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2024 | 90 | 1.350 |
Why?
|
| Seizures | 7 | 2018 | 871 | 1.200 |
Why?
|
| Carbonic Anhydrases | 5 | 2021 | 25 | 1.050 |
Why?
|
| Indans | 2 | 2016 | 53 | 1.050 |
Why?
|
| Rats, Wistar | 9 | 2021 | 359 | 1.040 |
Why?
|
| Adenosine A2 Receptor Antagonists | 5 | 2013 | 10 | 1.010 |
Why?
|
| Triazoles | 6 | 2017 | 138 | 1.010 |
Why?
|
| Molecular Dynamics Simulation | 5 | 2024 | 104 | 0.970 |
Why?
|
| Thiazoles | 3 | 2014 | 97 | 0.960 |
Why?
|
| Carbonic Anhydrase IX | 2 | 2021 | 15 | 0.940 |
Why?
|
| Benzothiazoles | 1 | 2024 | 27 | 0.920 |
Why?
|
| Acetylcholinesterase | 1 | 2024 | 20 | 0.920 |
Why?
|
| Carbazoles | 2 | 2025 | 31 | 0.920 |
Why?
|
| Molecular Structure | 8 | 2025 | 285 | 0.860 |
Why?
|
| Structure-Activity Relationship | 8 | 2025 | 568 | 0.850 |
Why?
|
| Catechin | 1 | 2021 | 13 | 0.750 |
Why?
|
| Polyphenols | 1 | 2021 | 19 | 0.750 |
Why?
|
| Epilepsy | 5 | 2021 | 859 | 0.700 |
Why?
|
| Phenylurea Compounds | 2 | 2016 | 48 | 0.630 |
Why?
|
| Pyrimidines | 5 | 2016 | 374 | 0.630 |
Why?
|
| Benzene Derivatives | 1 | 2018 | 19 | 0.610 |
Why?
|
| Neuroprotective Agents | 2 | 2016 | 146 | 0.600 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2018 | 60 | 0.600 |
Why?
|
| Receptor, Adenosine A2A | 3 | 2013 | 10 | 0.580 |
Why?
|
| Antidepressive Agents | 2 | 2016 | 287 | 0.540 |
Why?
|
| Animals | 24 | 2025 | 33720 | 0.540 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2025 | 1682 | 0.520 |
Why?
|
| Pentylenetetrazole | 5 | 2018 | 29 | 0.520 |
Why?
|
| Carbonic Anhydrase I | 4 | 2021 | 4 | 0.520 |
Why?
|
| Carbonic Anhydrase II | 4 | 2021 | 4 | 0.520 |
Why?
|
| Mice | 16 | 2025 | 17486 | 0.510 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 1677 | 0.500 |
Why?
|
| Computer Simulation | 4 | 2024 | 637 | 0.500 |
Why?
|
| Apoptosis | 3 | 2025 | 1780 | 0.500 |
Why?
|
| Heterocyclic Compounds | 1 | 2014 | 13 | 0.490 |
Why?
|
| Piperidines | 1 | 2016 | 198 | 0.490 |
Why?
|
| Central Nervous System Agents | 1 | 2014 | 15 | 0.480 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 105 | 0.450 |
Why?
|
| Osteosarcoma | 1 | 2017 | 257 | 0.450 |
Why?
|
| Antioxidants | 1 | 2016 | 337 | 0.440 |
Why?
|
| Microscopy, Electron, Transmission | 3 | 2019 | 119 | 0.430 |
Why?
|
| Cognition | 1 | 2018 | 735 | 0.430 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 427 | 0.400 |
Why?
|
| Cell Line | 5 | 2021 | 2774 | 0.390 |
Why?
|
| Mitochondria | 1 | 2017 | 678 | 0.390 |
Why?
|
| Rats | 6 | 2021 | 3631 | 0.370 |
Why?
|
| Thiones | 1 | 2010 | 9 | 0.350 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 2486 | 0.330 |
Why?
|
| Drug Discovery | 2 | 2021 | 171 | 0.300 |
Why?
|
| Peptide Fragments | 2 | 2024 | 748 | 0.300 |
Why?
|
| Mice, Nude | 2 | 2021 | 692 | 0.300 |
Why?
|
| Hydrogen Peroxide | 2 | 2019 | 113 | 0.290 |
Why?
|
| Humans | 24 | 2025 | 123152 | 0.290 |
Why?
|
| Protein Binding | 5 | 2016 | 1743 | 0.290 |
Why?
|
| Protein Isoforms | 2 | 2018 | 409 | 0.270 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2021 | 150 | 0.260 |
Why?
|
| Motor Activity | 4 | 2016 | 520 | 0.260 |
Why?
|
| Male | 12 | 2024 | 60038 | 0.260 |
Why?
|
| Models, Molecular | 4 | 2016 | 1070 | 0.250 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2025 | 24 | 0.240 |
Why?
|
| Protein Aggregates | 1 | 2025 | 29 | 0.240 |
Why?
|
| Maze Learning | 1 | 2024 | 125 | 0.220 |
Why?
|
| Acetamides | 1 | 2024 | 49 | 0.220 |
Why?
|
| Electroshock | 3 | 2018 | 28 | 0.220 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2025 | 142 | 0.210 |
Why?
|
| Dengue | 1 | 2023 | 112 | 0.200 |
Why?
|
| Dengue Virus | 1 | 2023 | 126 | 0.200 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 4268 | 0.200 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2021 | 54 | 0.190 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2021 | 94 | 0.190 |
Why?
|
| Zika Virus | 1 | 2023 | 142 | 0.190 |
Why?
|
| Syzygium | 1 | 2021 | 1 | 0.190 |
Why?
|
| Zika Virus Infection | 1 | 2023 | 167 | 0.180 |
Why?
|
| Seeds | 1 | 2021 | 42 | 0.180 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 213 | 0.180 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2021 | 137 | 0.180 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2021 | 243 | 0.170 |
Why?
|
| Haloperidol | 2 | 2010 | 22 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 1062 | 0.170 |
Why?
|
| Plant Extracts | 1 | 2021 | 120 | 0.170 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 352 | 0.160 |
Why?
|
| Antigens, Neoplasm | 1 | 2021 | 390 | 0.160 |
Why?
|
| Rotarod Performance Test | 2 | 2016 | 14 | 0.160 |
Why?
|
| Hyperglycemia | 1 | 2021 | 218 | 0.160 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 280 | 0.160 |
Why?
|
| Kindling, Neurologic | 1 | 2018 | 13 | 0.160 |
Why?
|
| Sulfinic Acids | 1 | 2018 | 1 | 0.150 |
Why?
|
| Convulsants | 1 | 2018 | 21 | 0.150 |
Why?
|
| In Vitro Techniques | 1 | 2019 | 966 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2018 | 64 | 0.150 |
Why?
|
| Methylation | 1 | 2018 | 227 | 0.150 |
Why?
|
| Cyclooxygenase 2 | 1 | 2018 | 158 | 0.140 |
Why?
|
| Hydrazines | 1 | 2016 | 28 | 0.140 |
Why?
|
| Postural Balance | 1 | 2018 | 124 | 0.140 |
Why?
|
| Protein Aggregation, Pathological | 1 | 2016 | 26 | 0.140 |
Why?
|
| Acetylcholine | 1 | 2016 | 82 | 0.130 |
Why?
|
| Crystallography, X-Ray | 2 | 2024 | 357 | 0.130 |
Why?
|
| Polypharmacology | 1 | 2016 | 4 | 0.130 |
Why?
|
| Cyclic AMP | 3 | 2013 | 247 | 0.130 |
Why?
|
| Myocytes, Cardiac | 1 | 2021 | 617 | 0.130 |
Why?
|
| Biological Availability | 1 | 2016 | 128 | 0.130 |
Why?
|
| Oxidative Stress | 1 | 2021 | 796 | 0.130 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 182 | 0.120 |
Why?
|
| Urea | 1 | 2016 | 210 | 0.120 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 434 | 0.120 |
Why?
|
| Ligands | 1 | 2016 | 533 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 222 | 0.120 |
Why?
|
| Cell Proliferation | 1 | 2021 | 2307 | 0.120 |
Why?
|
| Catalepsy | 2 | 2013 | 3 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 649 | 0.120 |
Why?
|
| Radioligand Assay | 2 | 2013 | 25 | 0.120 |
Why?
|
| Kinetics | 1 | 2016 | 1313 | 0.110 |
Why?
|
| HEK293 Cells | 2 | 2013 | 740 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 876 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2018 | 1167 | 0.110 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2013 | 39 | 0.110 |
Why?
|
| Behavior, Animal | 1 | 2016 | 477 | 0.110 |
Why?
|
| Receptors, Adenosine A2 | 1 | 2010 | 3 | 0.090 |
Why?
|
| Adenosine A2 Receptor Agonists | 1 | 2010 | 15 | 0.090 |
Why?
|
| Chromatography, Thin Layer | 1 | 2010 | 41 | 0.090 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2010 | 43 | 0.090 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 3277 | 0.080 |
Why?
|
| Naphthalenes | 1 | 2009 | 37 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 288 | 0.080 |
Why?
|
| Models, Biological | 1 | 2013 | 1442 | 0.080 |
Why?
|
| Cell Membrane | 1 | 2010 | 459 | 0.070 |
Why?
|
| Neoplasms | 1 | 2021 | 2766 | 0.070 |
Why?
|
| Movement Disorders | 1 | 2009 | 221 | 0.070 |
Why?
|
| Antipsychotic Agents | 1 | 2010 | 375 | 0.070 |
Why?
|
| Binding Sites | 2 | 2021 | 1292 | 0.070 |
Why?
|
| Catalytic Domain | 2 | 2016 | 160 | 0.060 |
Why?
|
| Epoxy Compounds | 1 | 2024 | 18 | 0.060 |
Why?
|
| Female | 2 | 2021 | 65442 | 0.050 |
Why?
|
| Mammals | 1 | 2023 | 262 | 0.050 |
Why?
|
| Phenols | 1 | 2021 | 58 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2021 | 141 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 2021 | 284 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2021 | 333 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2021 | 256 | 0.040 |
Why?
|
| Corpus Striatum | 2 | 2010 | 89 | 0.040 |
Why?
|
| Protein Transport | 1 | 2021 | 370 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2021 | 393 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2021 | 455 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2021 | 674 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2023 | 744 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 667 | 0.040 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2016 | 6 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1089 | 0.030 |
Why?
|
| Glucose | 1 | 2021 | 865 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2016 | 100 | 0.030 |
Why?
|
| 3-Mercaptopropionic Acid | 1 | 2015 | 1 | 0.030 |
Why?
|
| Semicarbazides | 1 | 2015 | 3 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2016 | 56 | 0.030 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2016 | 87 | 0.030 |
Why?
|
| Carbamates | 1 | 2015 | 57 | 0.030 |
Why?
|
| Status Epilepticus | 1 | 2015 | 139 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1402 | 0.030 |
Why?
|
| Mutation | 1 | 2025 | 5773 | 0.020 |
Why?
|
| Chloroquinolinols | 1 | 2010 | 1 | 0.020 |
Why?
|
| Acridines | 1 | 2010 | 8 | 0.020 |
Why?
|
| Phenethylamines | 1 | 2010 | 14 | 0.020 |
Why?
|
| Tritium | 1 | 2010 | 173 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2010 | 170 | 0.020 |
Why?
|
| Dopamine Antagonists | 1 | 2010 | 50 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2023 | 8103 | 0.020 |
Why?
|
| Adenosine | 1 | 2010 | 126 | 0.020 |
Why?
|
| Dopamine | 1 | 2009 | 275 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 6204 | 0.010 |
Why?
|